IP Library › Granted Patent US 7,374,930
Granted Patent B2
US 7,374,930 · App. 10/153,470 · Granted May 20, 2008

GLP-1 gene delivery for the treatment of type 2 diabetes

Assignee: Expression Genetics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,374,930
App. No.
10/153,470
Granted
May 20, 2008
Kind
B2
Abstract

This patent discloses compositions and methods of use thereof to normalize the blood glucose levels of patients with type 2 diabetes. It relates particularly to a plasmid comprising a chicken β actin promoter and enhancer; a modified GLP-1 (7-37) cDNA (pβGLP1), carrying a furin cleavage site, which is constructed and delivered into a cell for the expression of active GLP-1.

Claims (1)

1. A plasmid comprising the nucleotide sequence of SEQ ID NO:1.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2014
From: EGEN, INC.
To: CLSN LABORATORIES, INC.
Reel/Frame 033788/0539 →
CHANGE OF NAME Recorded Jul 27, 2011
From: EXPRESSION GENETICS, INC.
To: EGEN, INC.
Reel/Frame 026656/0425 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2002
From: OH, SEUNGJOON; LEE, MINHYUNG; KO, KYUNGSOO
To: EXPRESSION GENETICS, INC.
Reel/Frame 013245/0406 →
Continuity (1)
Related Publication 20030220274A1 · Nov 27, 2003